Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma

Int Cancer Conf J. 2016 Oct 11;6(1):25-28. doi: 10.1007/s13691-016-0266-6. eCollection 2017 Jan.

Abstract

Squamous cell carcinoma of the prostate is a rare tumor. It has been typically described as an aggressive cancer, with a median survival time of 14 months. We present a case of locally advanced squamous cell carcinoma of the prostate with a regional lymph node metastasis. The patient received a novel combination chemotherapy regimen, docetaxel, cisplatin, and 5-fluorouracil, with radiotherapy to the whole pelvis and prostate. He was subsequently treated with seven courses of docetaxel, cisplatin, and 5-fluorouracil chemotherapy without any severe adverse events. We identified a 60.1 % reduction in the prostatic tumor, and the lymph node metastasis was shrunk after chemotherapy. A needle biopsy of the prostate after chemotherapy revealed no malignancy. No recurrence has been observed for 24 months. A combination of docetaxel, cisplatin, and 5-fluorouracil chemotherapy and radiotherapy might be an effective therapy for squamous cell carcinoma of the prostate.

Keywords: Cisplatin; Docetaxel; Fluorouracil; Prostate; Squamous cell carcinoma.

Publication types

  • Case Reports